Asunto(s)
Lesiones Oculares/epidemiología , Personal Militar/estadística & datos numéricos , Procedimientos Quirúrgicos Oftalmológicos/estadística & datos numéricos , Oftalmólogos/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Heridas Relacionadas con la Guerra/epidemiología , Campaña Afgana 2001- , Lesiones Oculares/cirugía , Humanos , Guerra de Irak 2003-2011 , Medicina Militar , Estudios Retrospectivos , Estados Unidos , Heridas Relacionadas con la Guerra/cirugía , GuerraRESUMEN
Purpose: This work aimed to analyze the 100 most-cited articles on antivascular endothelial growth factor (anti-VEGF) inhibitors. Methods: A literature search for anti-VEGF inhibitors using the Web of Science was completed using the bibliographic databases for peer-reviewed literature published in Ophthalmology, the New England Journal of Medicine, Journal of the American Medical Association, and Lancet. Primary outcomes were the most frequently cited articles and journals with the most citations as well as the specific drug and disease process studied. Results: There were 42 696 cumulative citations among the top 100 articles. The articles were published between 2004 to 2016, with most articles published in 2006. Ophthalmology published the greatest number of articles among the top 100 at 48, whereas the New England Journal of Medicine has the most citations per publication at 1714. Ranibizumab was the medication researched in most articles at 56, followed by bevacizumab at 48, aflibercept at 10, and pegaptanib at 9. Forty-two articles investigated treatment of age-related macular degeneration, followed by 24 investigating diabetic macular edema, 10 for retinal vein occlusion, 8 for proliferative diabetic retinopathy, 2 for retinopathy of prematurity and polypoidal choroidal vasculopathy, and 1 for corneal neovascularization. Conclusions: As evidenced by the considerable number of citations accumulated over the past 20 years, anti-VEGF inhibitors have led to significant research in ophthalmology.
RESUMEN
A 24-year-old man was involved in a high-velocity motor vehicle accident with polytrauma 2 years after implantation of a copolymer phakic IOL (pIOL) (Visian ICL). After being released from the intensive care unit, he reported decreased vision, pain, glare, and photophobia and was treated for hyphema without globe rupture. He was found to be aniridic during anterior chamber washout of the hyphema. In the first reported case, to our knowledge, of aniridia after pIOL placement, blunt trauma likely caused expulsion of the iris through dehiscence of the previously placed wound for pIOL implantation.